Small is beautiful

Abstract

I ncreasingly, in health economics at least, small is beautiful. Forget analyses built on multinational mega-trials, healthcare purchasers and providers now need to know how your drug impacts on their regional, hospital and even practice budgets. So as purchasers and providers try to squeeze the last penny out of every healthcare dollar, a growing number of drug companies use micro-economic computer models to ensure that their pharmacoeconomic data are relevant to their local customers’ needs. But while customers welcome the approach, sponsors need to ensure that the approach doesn’t become devalued.